Clinical Trials Directory

Trials / Sponsors / IGM Biosciences, Inc.

IGM Biosciences, Inc.

Industry · 10 registered clinical trials.

StatusTrialPhaseStarted
TerminatedA Study of Imvotamab in Active, Refractory Idiopathic Inflammatory Myopathies
Idiopathic Inflammatory Myopathies, Inflammatory Myopathies
Phase 12024-05-29
TerminatedEvaluation of IGM-2644 in Adults With Relapsed and/or Refractory Multiple Myeloma
Multiple Myeloma
Phase 12023-08-29
TerminatedA Study of Imvotamab in Severe Systemic Lupus Erythematosus
Systemic Lupus Erythematosus, Lupus Erythematosus
Phase 12023-08-15
TerminatedA Phase 1b Study of Imvotamab in Moderate to Severe Rheumatoid Arthritis
Rheumatoid Arthritis, Arthritis, Rheumatoid, Arthritis
Phase 12023-03-15
CompletedEvaluation of IGM-7354 in Adults With Relapsed and/or Refractory Cancer
Solid Tumor
Phase 12023-01-10
TerminatedEvaluation of IGM-6268 in Healthy Adults and Patients With Mild to Moderate COVID-19
Healthy Volunteers, COVID-19
Phase 12022-01-20
TerminatedEvaluation of IGM-6268 in Healthy Volunteers
Healthy Volunteers
Phase 12021-12-07
TerminatedPhase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory,
Solid Tumor, Colorectal Cancer, Non Hodgkin Lymphoma
Phase 12020-09-23
TerminatedA Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma
Non-Hodgkin Lymphoma, Follicular Lymphoma, DLBCL
Phase 1 / Phase 22019-09-30
No Longer AvailableExpanded Access of Imvotamab (IGM-2323) in Patients With R/R NHL
Relapsed/Refractory Non-Hodgkin Lymphomas
——